|12.03|| +0.69 / +6.08%|
Cellular Biomedicine Group, Inc. is a biomedicine company. It engages in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The company's developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. It operates in two segments: Biomedicine and Consulting. The Biomedicine segment is in development stage, conducting research and development activities to commercialize stem cell and immune cell therapeutics, related tools and products. The Consulting segment provides services to foreign and domestic companies seeking access to the U.S. capital markets. Cellular Biomedicine Group was founded in 2009 and is headquartered in Palo Alto, CA.
|Bizuo Liu||CEO, CFO, Secretary & Director|
|Richard L. Wang||Chief Operating Officer|
|Maxwell Wang||Director-Medical Research|
|Yihong Yao||Chief Scientific Officer|
|Li Zhang||Vice President-Technology & Manufacturing|